News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)

Study Status:

Open For Enrollment

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo

Information: 

Principal Investigator
Fernando Membreno, MD
Sponsor
Madrigal Pharmaceuticals, Inc
Type of Trial
Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram